Mattson Financial Services LLC Invests $1.74 Million in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Mattson Financial Services LLC has invested approximately $1.74 million in Vertex Pharmaceuticals by acquiring 3,903 shares during the second quarter.
• Vertex Pharmaceuticals reported a net margin of 31.86% and earnings of $4.52 per share, exceeding analysts' expectations for the quarter.
• Currently, 90.96% of Vertex's stock is owned by institutional investors, indicating strong confidence among large financial backers.

Mattson Financial Services LLC acquired a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 3,903 shares of the pharmaceutical company's stock, valued at approximately $1,738,000.

Several other large investors also recently added to or reduced their stakes in VRTX. Price T Rowe Associates Inc. MD grew its position in Vertex Pharmaceuticals by 72.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,917,227 shares of the pharmaceutical company's stock valued at $1,414,331,000 after buying an additional 1,226,527 shares during the period. Nuveen LLC bought a new stake in Vertex Pharmaceuticals during the first quarter valued at approximately $484,053,000. Jennison Associates LLC grew its position in Vertex Pharmaceuticals by 17.2% during the first quarter. Jennison Associates LLC now owns 5,062,442 shares of the pharmaceutical company's stock valued at $2,454,373,000 after buying an additional 744,680 shares during the period. Goldman Sachs Group Inc. grew its position in Vertex Pharmaceuticals by 28.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,775,194 shares of the pharmaceutical company's stock valued at $860,650,000 after buying an additional 398,460 shares during the period. Finally, Alyeska Investment Group L.P. grew its position in Vertex Pharmaceuticals by 456.9% during the first quarter. Alyeska Investment Group L.P. now owns 431,804 shares of the pharmaceutical company's stock valued at $209,347,000 after buying an additional 354,269 shares during the period. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ:VRTX opened at $408.61 on Friday. The firm has a fifty day moving average price of $394.46 and a 200 day moving average price of $437.23. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.88. The firm has a market cap of $104.76 billion, a price-to-earnings ratio of 29.21 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The firm had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.90 billion. During the same quarter in the prior year, the business earned ($12.83) earnings per share. Vertex Pharmaceuticals's revenue for the quarter was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs bought 5,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The stock was purchased at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the transaction, the director owned 45,000 shares in the company, valued at $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.20% of the company's stock.

Analysts Set New Price Targets

VRTX has been the subject of several recent research reports. Leerink Partners upgraded shares of Vertex Pharmaceuticals from a "market perform" rating to an "outperform" rating and cut their target price for the company from $458.00 to $456.00 in a research report on Thursday, September 25th. HC Wainwright decreased their target price on shares of Vertex Pharmaceuticals from $550.00 to $478.00 and set a "buy" rating on the stock in a research note on Tuesday, August 5th. Morgan Stanley decreased their target price on shares of Vertex Pharmaceuticals from $439.00 to $438.00 and set an "equal weight" rating on the stock in a research note on Friday, October 10th. Stifel Nicolaus decreased their target price on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a "hold" rating on the stock in a research note on Tuesday, August 5th. Finally, Guggenheim decreased their target price on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a "buy" rating on the stock in a research note on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $494.38.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.